Skip directly to site content Skip directly to page options Skip directly to A-Z link
Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
Tuberculosis (TB)
    CDC Home
    • Facebook
    • Twitter
    • LinkedIn
    • Syndicate

    Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

    Minus
    Related Pages

    Note: This is the most current version of the guidelines (June 2013). The March 2014 MMWR notice refers to this version.

    (PDFpdf icon – 492K)

    Table of Contents

    • Introduction
    • Methodology for Preparation of these Guidelines
    • The Role of Rifamycins in Tuberculosis Treatment
    • Managing Drug Interactions with Antiretrovirals and Rifampin
    • Managing Drug Interactions with Antivirals and Rifabutin
    • Treatment of Latent TB Infection with Rifampin or Rifapentine
    • Treating Pregnant Women with Tuberculosis and HIV Co-infection
    • Treating Children with HIV-associated Tuberculosis
    • Co-treatment of Multidrug-resistant Tuberculosis and HIV
    • Limitations of these Guidelines
    • HIV-TB Drug Interaction Guideline Development Group
    • References
    • Table 1a. Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in adults
    • Table 1b.Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in children
    • Table 2a. Recommendations for co-administering antiretroviral drugs with RIFAMPIN in adults
    • Table 2b. Recommendations for co-administering antiretroviral drugs with RIFAMPIN in children
    • Table 3. Recommendations for co-administering antiretroviral drugs with RIFABUTIN in adults
    Page last reviewed: December 9, 2013
    Content source: Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
    homeTuberculosis
    • Basic TB Factsplus icon
      • How TB Spreads
      • Latent TB Infection and TB Disease
      • Signs & Symptoms
      • TB Risk Factors
      • Exposure to TB
      • TB Prevention
      • Vaccines
      • TB & HIV Coinfection
      • TB and Diabetes
      • TB Terms
    • Personal Stories
    • Testing & Diagnosisplus icon
      • Who Should be Tested
      • Testing for TB Infection
      • Testing in BCG-Vaccinated Persons
      • TB Screening and Testing of Health Care Personnel
      • Testing During Pregnancy
      • Diagnosing latent TB infection and TB disease
    • Treatmentplus icon
      • Deciding When to Treat Latent TB Infection
      • Treatment Regimens for Latent TB Infection (LTBI)
      • Treatment for TB Disease
      • Adverse Events
      • TB Treatment of Persons Living with HIV
      • TB Treatment and Pregnancy
      • TB Treatment for Children
      • Frequently Asked Questions
    • Drug-Resistant TB
    • Researchplus icon
      • TB Epidemiologic Studies Consortiumplus icon
        • Research Projects
        • Publications
      • TB Trials Consortiumplus icon
        • Study Descriptions
        • Background
      • Behavioral & Social Science Research
    • Health Care Settingsplus icon
      • TB Infection Control in Health Care Settings
      • Resources for TB Screening and Testing of Health Care Personnelplus icon
        • Frequently Asked Questions
    • TB in Specific Populationsplus icon
      • Health Disparities
      • Asian Persons
      • Black or African American Persons
      • Hispanic or Latino Persons
      • Children
      • Pregnancy
      • Correctional Facilities
      • People Experiencing Homelessness
      • International Travelers
    • Laboratory Informationplus icon
      • Drug Susceptibility Testing
      • False-Positive Investigation Toolkit
      • Interim Laboratory Biosafety Guidance for XDR tuberculosis strains
      • Model Performance Evaluation Program (MPEP)
      • Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus icon
        • Executive Summary
        • Introduction
        • Background on Tests for Molecular Detection of DR
        • General Considerations and Principles for a Molecular DR Testing Service
        • Possible Scenarios and Scope of Testing for a Molecular DR Testing Service
        • Research Needs
        • General Recommendations of the Expert Panel
        • Communication Plan for the Report
        • Recommendations
        • References
        • Panel Members and CDC Participants
        • Appendix 1
        • Appendix 2
        • Appendix 3
      • The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus icon
        • General Considerations
        • General Recommendations of the Expert Panel
        • Recommendations to ACET, CDC, DTBE
    • Data & Statisticsplus icon
      • TB Incidence in the United States
      • Reported TB in the US, 2021 Surveillance Reportplus icon
        • National Data
        • State & Local Data
        • Risk Factors
        • Demographics
        • TB Treatment and Case Outcomes
        • Drug-Resistant TB
        • Genotype Clusters
        • Estimates of Recent Transmission
      • Trends in Tuberculosis, 2021
      • Tuberculosis in the United States, 2021 (Slide Set)
      • Archived Surveillance Reports and Slide Sets
      • 2020 State and City Report
      • Archived State and City Reports
    • Professional Resources & Toolsplus icon
      • Tools for Healthcare Providersplus icon
        • Interactive Core Curriculum on Tuberculosis: What the Clinician Should Know
      • Resources for TB Programsplus icon
        • Strengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status Adjusters
        • Notice of Funding Opportunity (NOFO)
        • Program Evaluation
      • TB Centers of Excellence
      • TB Elimination Alliance
      • TB Genotypingplus icon
        • Conventional TB Genotyping
        • Whole Genome Sequencing
        • TB GIMS
        • Analytic Tools
      • Latent Tuberculosis Infection Resources
    • Publications & Productsplus icon
      • Patient and Public Materials
      • Fact Sheets
      • Guidelinesplus icon
        • Control & Elimination
        • Drug-Resistant TB
        • Infection Control & Prevention
        • Laboratory & Genotyping
        • TB & HIV
        • TB in Specific Populations
        • Testing & Diagnosis
        • Treatment
        • Vaccines & Immunizations
        • Archived TB Guidelines
      • Guides & Toolkitsplus icon
        • Aggregate Reports
        • CDC TB Surveillance Training
        • Core Curriculum
        • Effective TB Interviewing for Contact Investigation
        • Ethnographic Guides
        • False-Positive Investigation Toolkit
        • Forging Partnerships to Eliminate Tuberculosis
        • Guide to Application of Genotyping
        • LTBI: A Guide for Primary Health Care Providers
        • Mantoux Tuberculin Skin Testing Products
        • Report of Verified Case of Tuberculosis (RVCT)
        • Self-Study Modules
        • TB Contact Investigation Interviewing Skills Course
        • TB eDOT Toolkit
        • Understanding the TB Cohort Review Process
      • Newslettersplus icon
        • TB Notes, No. 4, 2022
        • TB Notes, No. 3, 2022
        • TB Notes, No. 2, 2022
        • TB Notes, No. 1, 2022
        • TB Notes, No. 4, 2021
        • TB Notes, No. 3, 2021
        • TB Notes, No. 2, 2021
        • TB Notes, No. 1, 2021
        • TB Notes, No. 4, 2020
        • TB Notes, No. 3, 2020
        • TB Notes, No. 2, 2020
        • TB Notes, No. 1, 2020
        • TB Notes, No. 4, 2019
        • TB Notes, No. 3, 2019
        • TB Notes, No. 2, 2019
        • TB Notes, No. 1, 2019
        • TB Notes, No. 6, 2018 
        • TB Notes, No. 5, 2018
        • TB Notes, No. 4, 2018
        • TB Notes, No. 3, 2018
        • TB Notes, No. 2, 2018
        • TB Notes, No. 1, 2018
        • TB Notes, No. 5, 2017
        • TB Notes, No. 4, 2017
        • TB Notes, No. 3, 2017
        • TB Notes, No. 2, 2017
        • TB Notes, No. 1, 2017
        • TB Notes, No. 5, 2016
        • TB Notes, No. 4, 2016
        • TB Notes, No. 3, 2016
        • TB Notes, No. 2, 2016
        • TB Notes, No. 1, 2016
      • Pamphlets, Brochures, Bookletsplus icon
        • Questions and Answers
        • Patient Education Series
        • Tuberculosis - Get the Facts
        • Tuberculosis - The Connection between TB and HIV
        • 12-Dose Regimen for Latent TB Infection-Patient Education Brochure
      • Postersplus icon
        • Mantoux Tuberculin Skin Test Wall Chart
        • World TB Day
        • Think TB
        • Stop TB
        • Take on TB
      • Reports & Articlesplus icon
        • DTBE Authored Journal Articles
        • Tuberculosis Laboratory Aggregate Reports
      • Slide Setsplus icon
        • Introduction to Tuberculosis
        • Epidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016
        • Self-Study Modules on Tuberculosis, 1-5 Slide Sets
        • The Tuberculosis (TB) in Correctional Settingsplus icon
          • Facilitator Guide
        • Introduction to TB Genotyping
        • Epidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017
        • Prevention and Control of Tuberculosis in Correctional and Detention Facilities
        • Guidelines for Preventing the Transmission of M. TB in Health care Settings
        • Investigation of Contacts of Persons with Infectious TB
        • Epidemiology of Pediatric Tuberculosis in the United States
        • Targeted Tuberculosis Testing and Treatment of Latent Tuberculosis Infection
      • Electronic Tools & Resources
      • Web-Based Courses & Webinarsplus icon
        • TB 101 for Health Care Workers
        • Interactive Core Curriculum
      • Content Syndication
      • Infographicsplus icon
        • Social Media Graphics
        • Customizable Take on TB Infographic with Instructions
    • Events
    • World TB Dayplus icon
      • Digital Toolkit
      • U.S. TB Championsplus icon
        • 2022 CDC U.S. TB Elimination Champions
        • 2021 CDC U.S. TB Elimination Champions
        • 2020 CDC U.S. TB Elimination Champions
        • 2019 CDC U.S. TB Elimination Champions
        • 2018 CDC U.S. TB Elimination Champions
        • 2017 CDC U.S. TB Elimination Champions
        • 2016 CDC U.S. TB Elimination Champions
      • Events
      • History
    • Featuresplus icon
      • TB Risk Factors
      • Treating Latent TB Infection with Short-Course Regimens
      • World Tuberculosis (TB) Day 2021
      • World Tuberculosis (TB) Day 2020
    • Linksplus icon
      • State TB Control Offices
    • About Usplus icon
      • Mission Statement and Activitiesplus icon
        • DTBE Strategic Plan
        • National TB Program Objectives
      • Organization Chart
      • Advisory Groupsplus icon
        • Federal TB Task Force
    email_03Subscribe to get TB updates

    To receive email updates about this page, enter your email address:

    What's this?
    • About CDC
    • Contact Us
    • 800-232-4636
    Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
    CONTACT CDC
    Contact Us
    Call 800-232-4636
    Email Us
    ABOUT CDC
    • About CDC
    • Jobs
    • Funding
    POLICIES
    • Accessibility
    • External Links
    • Privacy
    • Policies
    • No Fear Act
    • FOIA
    • OIG
    • Nondiscrimination
    • Vulnerability Disclosure Policy
    CONNECT WITH US
    • Facebook
    • Twitter
    • Instagram
    • LinkedIn
    • Youtube
    • Pinterest
    • Snapchat
    • Email
    LANGUAGES
    • Español
    • 繁體中文
    • Tiếng Việt
    • 한국어
    • Tagalog
    • Русский
    • العربية
    • Kreyòl Ayisyen
    • Français
    • Polski
    • Português
    • Italiano
    • Deutsch
    • 日本語
    • فارسی
    • English
    • U.S. Department of Health & Human Services
    • Accessibility
    • External Links
    • Privacy
    • Policies
    • No Fear Act
    • FOIA
    • Nondiscrimination
    • OIG
    • Vulnerability Disclosure Policy
    • USA.gov
    SAS stats

    Exit Notification / Disclaimer Policy

    Links with this icon indicate that you are leaving the CDC website.
    • The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
    • Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
    • You will be subject to the destination website's privacy policy when you follow the link.
    • CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
    For more information on CDC's web notification policies, see Website Disclaimers.
    CDC.gov Privacy Settings

    We take your privacy seriously. You can review and change the way we collect information below.

    These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

    Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.

    Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.

    Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.

    Remove all
    Confirmed!

    Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.

    Close